Gilbert & Cook Inc. Acquires New Position in Boston Scientific Corporation (NYSE:BSX)

Gilbert & Cook Inc. acquired a new position in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent filing with the SEC. The firm acquired 8,596 shares of the medical equipment provider’s stock, valued at approximately $239,000.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Boston Scientific Corporation by 2,181.6% in the first quarter. BlackRock Inc. now owns 95,744,545 shares of the medical equipment provider’s stock worth $2,381,169,000 after buying an additional 91,548,235 shares during the last quarter. FMR LLC raised its stake in Boston Scientific Corporation by 7.6% in the first quarter. FMR LLC now owns 184,708,390 shares of the medical equipment provider’s stock worth $4,593,698,000 after buying an additional 13,105,596 shares during the last quarter. MARSHALL WACE ASIA Ltd acquired a new stake in Boston Scientific Corporation during the first quarter worth $149,859,000. Marshall Wace North America L.P. acquired a new stake in Boston Scientific Corporation during the first quarter worth $149,859,000. Finally, Vanguard Group Inc. raised its stake in Boston Scientific Corporation by 4.0% in the first quarter. Vanguard Group Inc. now owns 91,134,744 shares of the medical equipment provider’s stock worth $2,266,521,000 after buying an additional 3,503,965 shares during the last quarter. Hedge funds and other institutional investors own 92.08% of the company’s stock.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 26.41 on Friday. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $28.51. The stock has a 50 day moving average of $27.34 and a 200-day moving average of $26.04. The firm has a market capitalization of $36.24 billion, a PE ratio of 47.25 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the company posted $0.27 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, equities research analysts anticipate that Boston Scientific Corporation will post $1.26 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/12/8596-shares-in-boston-scientific-corporation-nysebsx-acquired-by-gilbert-cook-inc-updated-updated.html.

BSX has been the topic of a number of research reports. Needham & Company LLC increased their price objective on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 22nd. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of Boston Scientific Corporation in a report on Wednesday, June 28th. Goldman Sachs Group, Inc. (The) began coverage on shares of Boston Scientific Corporation in a report on Tuesday, May 16th. They set a “neutral” rating and a $28.00 price target on the stock. Zacks Investment Research downgraded shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, BidaskClub downgraded shares of Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $30.06.

In other news, SVP John Bradley Sorenson sold 7,900 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $26.37, for a total transaction of $208,323.00. Following the completion of the transaction, the senior vice president now owns 21,680 shares of the company’s stock, valued at approximately $571,701.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP David A. Pierce sold 2,972 shares of the company’s stock in a transaction dated Friday, June 2nd. The shares were sold at an average price of $27.70, for a total transaction of $82,324.40. Following the transaction, the senior vice president now directly owns 28,572 shares of the company’s stock, valued at approximately $791,444.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 236,489 shares of company stock valued at $6,440,888. Corporate insiders own 0.74% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit